Nano-Engineered Stealth Cells for Auto-Destructive Recurrence Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies are limited in effectively identifying, studying, and manipulating specific subsets of glioma stem cells (GSCs) and myeloid-derived suppressor cells (MDSCs) for research, diagnosis, and therapy due to the lack of suitable tools, leading to challenges in understanding and counteracting their dissemination and therapy resistance, particularly in glioblastoma multiforme.
Innovation Solution
Reprogramming highly motile GSCs and MDSCs into 'therapeutic stealth cells' by sorting them from heterogeneous populations and delivering an oncolytic virus plasmid cocktail to render them auto-destructive, using nanotextured surfaces and chemoattractants to enhance motility and guide migration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional in vitro assays are used to study tumor cell behavior, then the assays are easier to perform, but they lack physiological relevance and only focus on bulk behavior of heterogeneous cellular populations
Solution Approach 1:
The patent uses microfabricated substrates with controlled topographical features (ridges and grooves) as intermediaries to bridge the gap between simple in vitro assays and complex in vivo conditions. These substrates provide physiological-relevant cues that guide cell migration and behavior while maintaining the controlled environment of in vitro experimentation, thus improving reliability without excessive operational complexity
Solution Approach 2:
The patent applies local quality by creating heterogeneous substrates with distinct regions of different topographical features (e.g., aligned ridges vs. random grooves, varying depths and orientations). This allows different regions to provide different physiological cues, enabling the study of localized cell behaviors and migration patterns that reflect the heterogeneity of tumor microenvironments while maintaining overall assay manageability
2Measurement precision
If current technologies are used to identify and study specific subsets of GSCs and MDSCs, then the existing tools are simpler to use, but they cannot effectively identify or manipulate specific cell subsets
Solution Approach 1:
The patent employs fluorescent markers and color-coded identification systems to distinguish specific cell subsets (GSCs and MDSCs) from heterogeneous populations. By tagging cells with fluorescent proteins or dyes that emit distinct colors, researchers can precisely identify and track specific cell types using standard fluorescence microscopy and flow cytometry, achieving high measurement precision without requiring overly complex analytical instruments
Solution Approach 2:
The patent introduces microfabricated substrates with specific topographical patterns as intermediaries that selectively interact with and enrich specific cell subsets based on their migratory properties. These substrates act as physical mediators that passively separate and concentrate target cells (e.g., highly migratory GSCs) from non-target cells, improving identification accuracy without requiring complex active sorting devices
3Reliability
If highly motile GSCs and MDSCs are sorted and reprogrammed into therapeutic stealth cells, then the therapeutic efficacy against tumor recurrence is improved, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent performs preliminary sorting and selection of highly motile GSCs and MDSCs from heterogeneous tumor populations before administering therapy. By pre-enriching for the specific cell subset most likely to cause recurrence and most responsive to the therapeutic reprogramming, the treatment achieves higher efficacy with lower complexity, as the preparatory step simplifies the subsequent therapeutic delivery by targeting a defined cell population rather than requiring complex combination therapies
Solution Approach 2:
The patent reprograms sorted GSCs and MDSCs to express therapeutic genes that enable them to autonomously seek out and destroy tumor recurrence sites. The modified cells serve themselves as both the delivery vehicle and the therapeutic agent, migrating to recurrence sites and releasing oncolytic viruses or other therapeutic payloads locally. This self-service approach improves efficacy by ensuring targeted delivery while reducing therapy complexity by eliminating the need for external guidance systems or complex dosing regimens
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The reprogrammed cells can effectively seek and destroy new tumor foci by enhancing their motility and targeting recurrence sites, providing a novel therapeutic approach to treat glioblastoma and other solid tumors.
Implementation Method 1
deterministic delivery of an anti-cancer agent, such as an oncolytic virus plasmid cocktail
Implementation Method 2
using nanotextured surfaces and chemoattractants to enhance motility and guide migration
Data Source
AI summary
Disclosed herein is a method of “reprogramming” highly motile cells found in tumors, such as these highly motile GSC and/or MDSC clones, into “auto-destructive” cell “missiles” (referred to herein as therapeutic stealth cells) that can seek and destroy new foci of recurrence within the body, such as the brain. Cells with enhanced motility can be sorted out from heterogeneous populations and then be rendered “auto-destructive” by deterministic delivery of an anti-cancer agent, such as an oncolytic virus plasmid cocktail.